SANDOZ ESTRADIOL DERM 100 PATCH
Land: Kanada
Tungumál: enska
Heimild: Health Canada
Vara einkenni
(SPC)
25-03-2009
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
ESTRADIOL (ESTRADIOL HEMIHYDRATE)
Fáanlegur frá:
SANDOZ CANADA INCORPORATED
ATC númer:
G03CA03
INN (Alþjóðlegt nafn):
ESTRADIOL
Skammtar:
100MCG
Lyfjaform:
PATCH
Samsetning:
ESTRADIOL (ESTRADIOL HEMIHYDRATE) 100MCG
Stjórnsýsluleið:
TRANSDERMAL
Einingar í pakka:
8
Gerð lyfseðils:
Prescription
Lækningarsvæði:
ESTROGENS
Vörulýsing:
Active ingredient group (AIG) number: 0106457037; AHFS:
Leyfisstaða:
APPROVED
Leyfisdagur:
2006-01-11
Vara einkenni
PRODUCT MONOGRAPH
SANDOZ ESTRADIOL DERM 50, 75 AND 100 ESTRADIOL HEMIHYDRATE (ESTRADIOL-17Β)
TRANSDERMAL THERAPEUTIC SYSTEM
4, 6 AND 8 MG ESTRADIOL PATCHES
CORRESPONDING TO
50 MCG/DAY, 75 MCG/DAY AND 100 MCG/DAY DELIVERY
ESTROGEN
Sandoz Canada Inc.
145 Jules-Léger
Date of Revision: March 19, 2009
Boucherville, QC, Canada
J4B 7K8
CONTROL NUMBER: 120474
_ _
_Sandoz Estradiol Derm _
_Page 2 of 34 _
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION.........................................................................................
3
SUMMARY
PRODUCT
INFORMATION...............................................................................................................
3
INDICATIONS
AND
CLINICAL
USE
....................................................................................................................
3
CONTRAINDICATIONS
.........................................................................................................................................
3
WARNINGS
AND
PRECAUTIONS
........................................................................................................................
4
ADVERSE
REACTIONS........................................................................................................................................
11
DRUG
INTERACTIONS
........................................................................................................................................
12
DOSAGE
AND
ADMINISTRATION
....................................................................................................................
14
OVERDOSAGE
......................................................................................................................................................
16
ACTIONS
AND
CLINICAL
PHARMACOLOGY.................................................................................................
16
STORAGE
AND
STABILITY
.....................................................................................................................
Lestu allt skjalið
